Related references
Note: Only part of the references are listed.Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
M. Lae et al.
ANNALS OF ONCOLOGY (2010)
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
Raj S. Pruthi et al.
BJU INTERNATIONAL (2010)
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
Christian Bolenz et al.
BJU INTERNATIONAL (2010)
A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
Christian Wuelfing et al.
CANCER (2009)
The Updated EAU Guidelines on Muscle-Invasive and Metastatic Madder Cancer
Arnulf Stenzl et al.
EUROPEAN UROLOGY (2009)
Epidemiology and genetic susceptibility to bladder cancer
Xifeng Wu et al.
BJU INTERNATIONAL (2008)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
Marko Babjuk et al.
EUROPEAN UROLOGY (2008)
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas
Vildan Caner et al.
PATHOLOGY & ONCOLOGY RESEARCH (2008)
Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail
Fredrik Liedberg et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy
Surendra B. Kolla et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2008)
Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update
M. Craig Hall et al.
JOURNAL OF UROLOGY (2007)
Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo
A. J. Colquhoun et al.
JOURNAL OF RADIATION RESEARCH (2007)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Yuh-Shyan Tsai et al.
UROLOGIA INTERNATIONALIS (2007)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Bladder cancer: Epidemiology, staging and grading, and diagnosis
Z Kirkali et al.
UROLOGY (2005)
Expression of Her2/neu in locally advanced bladder cancer:: Implication for a molecular targeted therapy
C Wülfing et al.
AKTUELLE UROLOGIE (2005)
erbB receptor expression patterns in human bladder cancer
PH Rajjayabun et al.
UROLOGY (2005)
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group
A Chakravarti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
SB Maddineni et al.
BRITISH JOURNAL OF CANCER (2005)
HER-2 and TOP2A coamplification in urinary bladder cancer
R Simon et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan
YS Tsai et al.
UROLOGIA INTERNATIONALIS (2003)
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
R Gandour-Edwards et al.
CANCER (2002)
Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy
JE Gschwend et al.
EUROPEAN UROLOGY (2002)
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
JP Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
